ArticleProceedings (Baylor University. Medical Center)2025
How does mycosis fungoides affect quality of life? Comparative evaluation of the Dermatology Life Quality Index in patients with mycosis fungoides and psoriasis.
Article in Proceedings (Baylor University. Medical Center), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Psychological Distress, Symptom Burden and Quality of Life in Patients with Mycosis Fungoides and Sézary Syndrome.Acta dermato-venereologica · 2026Observational
- Quality of life in mycosis fungoides.Proceedings (Baylor University. Medical Center) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mycosis fungoides is a chronic cutaneous lymphoma that requires close follow up due to frequent recurrences. Although quality of life has an important role in cancer management, it is generally not evaluated in patients with mycosis fungoides. The Dermatology Life Quality Index (DLQI) questionnaire is a validated skin-specific quality of life index, with answers scored on a scale from 0 to 30. Higher scores are considered as demonstrating a high impact on quality of life. Herein, we compared DLQI scores in patients with mycosis fungoides and psoriasis. Methods: Medical records of patients admitted to the dermatology outpatient clinic between March 2023 and May 2023 were reviewed retrospectively. Afterward, the patients were contacted by phone to answer the questions on the DLQI. Results: This study included a total of 110 patients, 60 with psoriasis and 50 with mycosis fungoides. The median DLQI score was 4 (standard deviation [SD] 8) (range 0-24) in psoriasis patients and 1 (SD 4) (range 0-19) in patients with mycosis fungoides ( Conclusion: Since various factors such as lesion type, lesion location, symptoms, and treatment significantly affect the DLQI, and DLQI subgroups were affected similarly to patients with psoriasis, we suggest considering DLQI scores when determining the most appropriate treatment option in patients with mycosis fungoides.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.